Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer
Background The treatment for stage III non-small cell lung cancer (NSCLC) often involves multi-modality treatment. This retrospective study aimed to evaluate whether multidisciplinary team (MDT) discussion results in better patient survival. Materials and methods MDT discussion was optional before F...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-10, Vol.15 (10), p.e0236503-e0236503 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0236503 |
|---|---|
| container_issue | 10 |
| container_start_page | e0236503 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Hung, Hsiu-Ying Tseng, Yen-Han Chao, Heng-Sheng Chiu, Chao-Hua Hsu, Wen-Hu Hsu, Han-Shui Wu, Yu-Chung Chou, Teh-Ying Chen, Chun-Ku Lan, Keng-Li Chen, Yi-Wei Wu, Yuan-Hung Chen, Yuh-Min |
| description | Background The treatment for stage III non-small cell lung cancer (NSCLC) often involves multi-modality treatment. This retrospective study aimed to evaluate whether multidisciplinary team (MDT) discussion results in better patient survival. Materials and methods MDT discussion was optional before February 2016 and was actively encouraged by the MDT committee beginning February 2016. We reviewed the medical charts and computer records of patients with stage III NSCLC between January 2013 and December 2018. Results A total of 515 patients were included. The median survival of all the patients was 33.9 months (M). The median survival of patients who were treated after MDT discussion was 41.2 M and that of patients treated without MDT discussion was 25.7 M (p = 0.018). The median survival of patients treated before February 2016 was 25.7 M and that of patients treated after February 2016 was 33.9 M (p = 0.003). The median survival of patients with stage IIIA tumors and those with stage IIIB tumors was 39.4 M and 25.7 M, respectively (p = 0.141). Multivariate analysis showed that MDT or not (p |
| doi_str_mv | 10.1371/journal.pone.0236503 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2449456630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A637815214</galeid><doaj_id>oai_doaj_org_article_cefc9aea12fd45a7a119d50a6fb0d6d7</doaj_id><sourcerecordid>A637815214</sourcerecordid><originalsourceid>FETCH-LOGICAL-c669t-3bcb8db432365e6a279fb5266b9b974f8eaa2c453fbebd800d7f4fc9d9e7e7bf3</originalsourceid><addsrcrecordid>eNqNk12LEzEUhgdR3LX6DwQDguhFa2aSyXRuhGXxo7Cy4NdtOJM5aVMySTfJVP33ZmyVreyF5CLh5Ml7ct7kFMXTki5K1pSvt34MDuxi5x0uaMVETdm94rxsWTUXFWX3b63Pikcxbimt2VKIh8UZY5Rlkfq8SB9Hm0xvojI7axyEnyQhDGSKjDEa70jAmJlIjCNxDHuzB0s6dKhNItoHsoNk0GXgu0kbEhOskaxWK-K8m8cBrJ0rtJbY0a2JAqcwPC4eaLARnxznWfH13dsvlx_mV9fvV5cXV3MlRJvmrFPdsu84m4pDAVXT6q6uhOjarm24XiJApXjNdIddv6S0bzTXqu1bbLDpNJsVzw66O-ujPBoWZcV5y2shsgmzYnUgeg9buQtmyA5ID0b-DviwlhCSURalwiwNCGWle15DA2XZ9jUFoTvai77JWm-O2cZuwF5lTwLYE9HTHWc2cu33sqk5p8vpMi-PAsHfjBiTHPIrZO_AoR8P925rTvmEPv8Hvbu6I7WGXIBx2ue8ahKVF4I1y7KuSp6pxR1UHj0ORvnpoXP85MCrkwOZSfgjrSF_GLn6_On_2etvp-yLW-wGwaZN9HZM-RfGU5AfQBV8jAH1X5NLKqfm-OOGnJpDHpuD_QLbigMv</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2449456630</pqid></control><display><type>article</type><title>Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Hung, Hsiu-Ying ; Tseng, Yen-Han ; Chao, Heng-Sheng ; Chiu, Chao-Hua ; Hsu, Wen-Hu ; Hsu, Han-Shui ; Wu, Yu-Chung ; Chou, Teh-Ying ; Chen, Chun-Ku ; Lan, Keng-Li ; Chen, Yi-Wei ; Wu, Yuan-Hung ; Chen, Yuh-Min</creator><creatorcontrib>Hung, Hsiu-Ying ; Tseng, Yen-Han ; Chao, Heng-Sheng ; Chiu, Chao-Hua ; Hsu, Wen-Hu ; Hsu, Han-Shui ; Wu, Yu-Chung ; Chou, Teh-Ying ; Chen, Chun-Ku ; Lan, Keng-Li ; Chen, Yi-Wei ; Wu, Yuan-Hung ; Chen, Yuh-Min</creatorcontrib><description>Background The treatment for stage III non-small cell lung cancer (NSCLC) often involves multi-modality treatment. This retrospective study aimed to evaluate whether multidisciplinary team (MDT) discussion results in better patient survival. Materials and methods MDT discussion was optional before February 2016 and was actively encouraged by the MDT committee beginning February 2016. We reviewed the medical charts and computer records of patients with stage III NSCLC between January 2013 and December 2018. Results A total of 515 patients were included. The median survival of all the patients was 33.9 months (M). The median survival of patients who were treated after MDT discussion was 41.2 M and that of patients treated without MDT discussion was 25.7 M (p = 0.018). The median survival of patients treated before February 2016 was 25.7 M and that of patients treated after February 2016 was 33.9 M (p = 0.003). The median survival of patients with stage IIIA tumors and those with stage IIIB tumors was 39.4 M and 25.7 M, respectively (p = 0.141). Multivariate analysis showed that MDT or not (p<0.001), T staging (p = 0.009), performance status (p<0.001), and surgery (p = 0.016) to be significant prognostic factors. Conclusion The results of the study show that MDT discussion results in survival benefit in patients with stage III NSCLC. The MDT discussion, performance status, and if surgery was performed were independent prognostic factors for patients with stage III NSCLC.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0236503</identifier><identifier>PMID: 33031375</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Biology and Life Sciences ; Cancer therapies ; Care and treatment ; Chemotherapy ; Discussion ; Health care teams ; Hospitals ; Immunotherapy ; Lung cancer ; Lung diseases ; Medicine ; Medicine and Health Sciences ; Methods ; Multivariate analysis ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Oncology ; Patients ; People and Places ; Physical Sciences ; Physicians ; Practice ; Quality of life ; Research and Analysis Methods ; Small cell lung carcinoma ; Surgery ; Survival ; Thoracic surgery ; Tumors</subject><ispartof>PloS one, 2020-10, Vol.15 (10), p.e0236503-e0236503</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Hung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Hung et al 2020 Hung et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c669t-3bcb8db432365e6a279fb5266b9b974f8eaa2c453fbebd800d7f4fc9d9e7e7bf3</citedby><cites>FETCH-LOGICAL-c669t-3bcb8db432365e6a279fb5266b9b974f8eaa2c453fbebd800d7f4fc9d9e7e7bf3</cites><orcidid>0000-0002-7504-0678</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544080/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544080/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids></links><search><creatorcontrib>Hung, Hsiu-Ying</creatorcontrib><creatorcontrib>Tseng, Yen-Han</creatorcontrib><creatorcontrib>Chao, Heng-Sheng</creatorcontrib><creatorcontrib>Chiu, Chao-Hua</creatorcontrib><creatorcontrib>Hsu, Wen-Hu</creatorcontrib><creatorcontrib>Hsu, Han-Shui</creatorcontrib><creatorcontrib>Wu, Yu-Chung</creatorcontrib><creatorcontrib>Chou, Teh-Ying</creatorcontrib><creatorcontrib>Chen, Chun-Ku</creatorcontrib><creatorcontrib>Lan, Keng-Li</creatorcontrib><creatorcontrib>Chen, Yi-Wei</creatorcontrib><creatorcontrib>Wu, Yuan-Hung</creatorcontrib><creatorcontrib>Chen, Yuh-Min</creatorcontrib><title>Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer</title><title>PloS one</title><description>Background The treatment for stage III non-small cell lung cancer (NSCLC) often involves multi-modality treatment. This retrospective study aimed to evaluate whether multidisciplinary team (MDT) discussion results in better patient survival. Materials and methods MDT discussion was optional before February 2016 and was actively encouraged by the MDT committee beginning February 2016. We reviewed the medical charts and computer records of patients with stage III NSCLC between January 2013 and December 2018. Results A total of 515 patients were included. The median survival of all the patients was 33.9 months (M). The median survival of patients who were treated after MDT discussion was 41.2 M and that of patients treated without MDT discussion was 25.7 M (p = 0.018). The median survival of patients treated before February 2016 was 25.7 M and that of patients treated after February 2016 was 33.9 M (p = 0.003). The median survival of patients with stage IIIA tumors and those with stage IIIB tumors was 39.4 M and 25.7 M, respectively (p = 0.141). Multivariate analysis showed that MDT or not (p<0.001), T staging (p = 0.009), performance status (p<0.001), and surgery (p = 0.016) to be significant prognostic factors. Conclusion The results of the study show that MDT discussion results in survival benefit in patients with stage III NSCLC. The MDT discussion, performance status, and if surgery was performed were independent prognostic factors for patients with stage III NSCLC.</description><subject>Biology and Life Sciences</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Discussion</subject><subject>Health care teams</subject><subject>Hospitals</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Multivariate analysis</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>People and Places</subject><subject>Physical Sciences</subject><subject>Physicians</subject><subject>Practice</subject><subject>Quality of life</subject><subject>Research and Analysis Methods</subject><subject>Small cell lung carcinoma</subject><subject>Surgery</subject><subject>Survival</subject><subject>Thoracic surgery</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12LEzEUhgdR3LX6DwQDguhFa2aSyXRuhGXxo7Cy4NdtOJM5aVMySTfJVP33ZmyVreyF5CLh5Ml7ct7kFMXTki5K1pSvt34MDuxi5x0uaMVETdm94rxsWTUXFWX3b63Pikcxbimt2VKIh8UZY5Rlkfq8SB9Hm0xvojI7axyEnyQhDGSKjDEa70jAmJlIjCNxDHuzB0s6dKhNItoHsoNk0GXgu0kbEhOskaxWK-K8m8cBrJ0rtJbY0a2JAqcwPC4eaLARnxznWfH13dsvlx_mV9fvV5cXV3MlRJvmrFPdsu84m4pDAVXT6q6uhOjarm24XiJApXjNdIddv6S0bzTXqu1bbLDpNJsVzw66O-ujPBoWZcV5y2shsgmzYnUgeg9buQtmyA5ID0b-DviwlhCSURalwiwNCGWle15DA2XZ9jUFoTvai77JWm-O2cZuwF5lTwLYE9HTHWc2cu33sqk5p8vpMi-PAsHfjBiTHPIrZO_AoR8P925rTvmEPv8Hvbu6I7WGXIBx2ue8ahKVF4I1y7KuSp6pxR1UHj0ORvnpoXP85MCrkwOZSfgjrSF_GLn6_On_2etvp-yLW-wGwaZN9HZM-RfGU5AfQBV8jAH1X5NLKqfm-OOGnJpDHpuD_QLbigMv</recordid><startdate>20201008</startdate><enddate>20201008</enddate><creator>Hung, Hsiu-Ying</creator><creator>Tseng, Yen-Han</creator><creator>Chao, Heng-Sheng</creator><creator>Chiu, Chao-Hua</creator><creator>Hsu, Wen-Hu</creator><creator>Hsu, Han-Shui</creator><creator>Wu, Yu-Chung</creator><creator>Chou, Teh-Ying</creator><creator>Chen, Chun-Ku</creator><creator>Lan, Keng-Li</creator><creator>Chen, Yi-Wei</creator><creator>Wu, Yuan-Hung</creator><creator>Chen, Yuh-Min</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7504-0678</orcidid></search><sort><creationdate>20201008</creationdate><title>Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer</title><author>Hung, Hsiu-Ying ; Tseng, Yen-Han ; Chao, Heng-Sheng ; Chiu, Chao-Hua ; Hsu, Wen-Hu ; Hsu, Han-Shui ; Wu, Yu-Chung ; Chou, Teh-Ying ; Chen, Chun-Ku ; Lan, Keng-Li ; Chen, Yi-Wei ; Wu, Yuan-Hung ; Chen, Yuh-Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c669t-3bcb8db432365e6a279fb5266b9b974f8eaa2c453fbebd800d7f4fc9d9e7e7bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biology and Life Sciences</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Discussion</topic><topic>Health care teams</topic><topic>Hospitals</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Multivariate analysis</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>People and Places</topic><topic>Physical Sciences</topic><topic>Physicians</topic><topic>Practice</topic><topic>Quality of life</topic><topic>Research and Analysis Methods</topic><topic>Small cell lung carcinoma</topic><topic>Surgery</topic><topic>Survival</topic><topic>Thoracic surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hung, Hsiu-Ying</creatorcontrib><creatorcontrib>Tseng, Yen-Han</creatorcontrib><creatorcontrib>Chao, Heng-Sheng</creatorcontrib><creatorcontrib>Chiu, Chao-Hua</creatorcontrib><creatorcontrib>Hsu, Wen-Hu</creatorcontrib><creatorcontrib>Hsu, Han-Shui</creatorcontrib><creatorcontrib>Wu, Yu-Chung</creatorcontrib><creatorcontrib>Chou, Teh-Ying</creatorcontrib><creatorcontrib>Chen, Chun-Ku</creatorcontrib><creatorcontrib>Lan, Keng-Li</creatorcontrib><creatorcontrib>Chen, Yi-Wei</creatorcontrib><creatorcontrib>Wu, Yuan-Hung</creatorcontrib><creatorcontrib>Chen, Yuh-Min</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hung, Hsiu-Ying</au><au>Tseng, Yen-Han</au><au>Chao, Heng-Sheng</au><au>Chiu, Chao-Hua</au><au>Hsu, Wen-Hu</au><au>Hsu, Han-Shui</au><au>Wu, Yu-Chung</au><au>Chou, Teh-Ying</au><au>Chen, Chun-Ku</au><au>Lan, Keng-Li</au><au>Chen, Yi-Wei</au><au>Wu, Yuan-Hung</au><au>Chen, Yuh-Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer</atitle><jtitle>PloS one</jtitle><date>2020-10-08</date><risdate>2020</risdate><volume>15</volume><issue>10</issue><spage>e0236503</spage><epage>e0236503</epage><pages>e0236503-e0236503</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Background The treatment for stage III non-small cell lung cancer (NSCLC) often involves multi-modality treatment. This retrospective study aimed to evaluate whether multidisciplinary team (MDT) discussion results in better patient survival. Materials and methods MDT discussion was optional before February 2016 and was actively encouraged by the MDT committee beginning February 2016. We reviewed the medical charts and computer records of patients with stage III NSCLC between January 2013 and December 2018. Results A total of 515 patients were included. The median survival of all the patients was 33.9 months (M). The median survival of patients who were treated after MDT discussion was 41.2 M and that of patients treated without MDT discussion was 25.7 M (p = 0.018). The median survival of patients treated before February 2016 was 25.7 M and that of patients treated after February 2016 was 33.9 M (p = 0.003). The median survival of patients with stage IIIA tumors and those with stage IIIB tumors was 39.4 M and 25.7 M, respectively (p = 0.141). Multivariate analysis showed that MDT or not (p<0.001), T staging (p = 0.009), performance status (p<0.001), and surgery (p = 0.016) to be significant prognostic factors. Conclusion The results of the study show that MDT discussion results in survival benefit in patients with stage III NSCLC. The MDT discussion, performance status, and if surgery was performed were independent prognostic factors for patients with stage III NSCLC.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>33031375</pmid><doi>10.1371/journal.pone.0236503</doi><tpages>e0236503</tpages><orcidid>https://orcid.org/0000-0002-7504-0678</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-10, Vol.15 (10), p.e0236503-e0236503 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2449456630 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Biology and Life Sciences Cancer therapies Care and treatment Chemotherapy Discussion Health care teams Hospitals Immunotherapy Lung cancer Lung diseases Medicine Medicine and Health Sciences Methods Multivariate analysis Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients People and Places Physical Sciences Physicians Practice Quality of life Research and Analysis Methods Small cell lung carcinoma Surgery Survival Thoracic surgery Tumors |
| title | Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T15%3A37%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multidisciplinary%20team%20discussion%20results%20in%20survival%20benefit%20for%20patients%20with%20stage%20III%20non-small-cell%20lung%20cancer&rft.jtitle=PloS%20one&rft.au=Hung,%20Hsiu-Ying&rft.date=2020-10-08&rft.volume=15&rft.issue=10&rft.spage=e0236503&rft.epage=e0236503&rft.pages=e0236503-e0236503&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0236503&rft_dat=%3Cgale_plos_%3EA637815214%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2449456630&rft_id=info:pmid/33031375&rft_galeid=A637815214&rft_doaj_id=oai_doaj_org_article_cefc9aea12fd45a7a119d50a6fb0d6d7&rfr_iscdi=true |